Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 9.95% | -14.58% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.95% | -14.58% | |||
| Cost of Revenue | 7.96% | -18.86% | |||
| Gross Profit | 11.76% | -10.27% | |||
| SG&A Expenses | -0.14% | -2.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.68% | -11.71% | |||
| Operating Income | 111.63% | -44.07% | |||
| Income Before Tax | 178.59% | -174.24% | |||
| Income Tax Expenses | 204.92% | -177.77% | |||
| Earnings from Continuing Operations | 170.46% | -173.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 170.46% | -173.21% | |||
| EBIT | 111.63% | -44.07% | |||
| EBITDA | 51.26% | -27.60% | |||
| EPS Basic | 171.02% | -173.26% | |||
| Normalized Basic EPS | 84.01% | -43.92% | |||
| EPS Diluted | 170.83% | -173.37% | |||
| Normalized Diluted EPS | 83.55% | -43.84% | |||
| Average Basic Shares Outstanding | -0.79% | -0.07% | |||
| Average Diluted Shares Outstanding | -0.53% | -0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||